AstraZeneca’s Tagrisso improves survival in first-line lung cancer

Results from the Phase 3 FLAURA study evaluating AstraZeneca’s (NYSE:AZN) Tagrisso (osimertinib) in treatment-naive patients with locally advanced/metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC) showed a statistically significant improvement in overall survival (OS) compared to Iressa (gefitinib) and Astellas Pharma (OTCPK:ALPMF) and Roche’s (OTCQX:RHHBY) Tarceva (erlotinib), both standard-of-care treatments.

Complete data will be presented at an upcoming medical conference.

Shares are up 2% premarket on average volume.

https://seekingalpha.com/news/3490259-astrazenecas-tagrisso-improves-survival-first-line-lung-cancer-shares-2-percent-premarket